Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Abstract

In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reductions and clinical benefit in patients with PV have not been extensively evaluated in a randomized trial. This… (More)
DOI: 10.1007/s00277-017-2994-x

Topics

10 Figures and Tables

Cite this paper

@inproceedings{Vannucchi2017RuxolitinibRJ, title={Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study}, author={Alessandro Maria Vannucchi and Srdan Verstovsek and Paola Guglielmelli and Martin Griesshammer and Timothy C. Burn and Ahmad B Naim and Dilan C. Paranagama and Mahtab Marker and Brian Gadbaw and Jean-Jacques Kiladjian}, booktitle={Annals of Hematology}, year={2017} }